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We evaluated outcomes and associated prognostic factors in 233 patients undergoing allogeneic hemato-
poietic cell transplantation (HCT) for primary myeloﬁbrosis (MF) using reduced-intensity conditioning (RIC).
The median age at RIC HCT was 55 yr. Donors were a matched sibling donor (MSD) in 34% of RIC HCTs, an HLA
well-matched unrelated donor (URD) in 45%, and a partially matched/mismatched URD in 21%. Risk strati-
ﬁcation according to the Dynamic International Prognostic Scoring System (DIPSS) was 12% low, 49%
intermediate-1, 37% intermediate-2, and 1% high. The probability of survival at 5 yr was 47% (95% conﬁdence
interval [CI], 40% to 53%). In a multivariate analysis, donor type was the sole independent factor associated
with survival. Adjusted probabilities of survival at 5-yr were 56% (95% CI, 44% to 67%) for MSD, 48% (95% CI,
37% to 58%) for well-matched URD, and 34% (95% CI, 21% to 47%) for partially matched/mismatched URD
(P ¼ .002). The relative risk (RR) for NRM was 3.92 (P ¼ .006) for well-matched URD and 9.37 (P < .0001) for
partially matched/mismatched URD. Trends toward increased NRM (RR, 1.7; P ¼ .07) and inferior survival (RR,dgments on page 96.
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V. Gupta et al. / Biol Blood Marrow Transplant 20 (2014) 89e97901.37; P ¼ .10) were observed in DIPSS intermediate-2/high-risk patients compared with DIPSS low/
intermediate-1 risk patients. Our data indicate that RIC HCT is a potentially curative option for patients
with MF, and that donor type is the most important factor inﬂuencing survival in these patients.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Primary myeloﬁbrosis (MF) is a clonal stem cell disorder
characterized by cytopenias, splenomegaly, marrow ﬁbrosis,
and systemic symptoms resulting from elevated inﬂamma-
tory cytokine levels. Allogeneic hematopoietic cell trans-
plantation (HCT) is the only known curative treatment
option for MF. Full-intensity conditioning (FIC) in older pa-
tients with MF is associated with high rates of nonrelapse
mortality (NRM), restricting the use of this option to younger
and ﬁtter patients [1]. Reduced-intensity conditioning (RIC)
is increasingly used in patients with MF, as demonstrated by
the trends reported by the Center for International Blood and
Marrow Transplant Research (CIBMTR) [1].
The outcome of HCT is usually determined by complex
interactions among various patient-, disease-, and trans-
plantation-related variables. Although potentially curative,
HCT in patients withMF is associated with signiﬁcant risks of
morbidity and mortality. Thus, it is important to understand
the factors associated with outcomes to determine which
patients are likely to beneﬁt from this approach. Previous
studies evaluating the prognostic factors in patients with MF
undergoing HCT have reported conﬂicting results [2-6],
likely related to heterogeneity of the disease and patient
populations, as well as small sample sizes lacking statistical
power, and thus the inability to analyze these factors in
multivariate analysis.
Our understanding of the natural history of primary MF
has improved signiﬁcantly with the evolution of new prog-
nostic systems. These prognostic systems are important tools
for assessing the risk of mortality associatedwith the disease,
and thus can be useful in determining the candidacy for HCT.
Lille score, the conventional prognostic scoring system, di-
vides patients into low-, intermediate-, and high-risk cate-
gories [7]. The International Prognostic Scoring System (IPSS)
was recently developed by the International Working Group
of Myeloﬁbrosis Research and Treatment [8]. Five indepen-
dent risk factors at diagnosisdage >65 yr, hemoglobin <100
g/L, WBC count >25  109/L, circulating blasts >1%, and
presence of constitutional symptomsdwere predictive of
shorter survival in patients with primaryMF. The presence of
0, 1, 2, and 3 factors are categorized as low-, intermediate-
1-, intermediate 2-, and high-risk disease, respectively, with
correspondingmedian survival of 135, 95, 48, and 27mo. The
risk factors for IPSS were also validated in a time-dependent
fashion known as dynamic IPSS (DIPSS) [9]. DIPSS is used to
assess the risk of mortality at any time during the course of
disease. Further reﬁnement of DIPSS was proposed by
incorporating cytogenetics, transfusion dependence, and
thrombocytopenia to create the DIPSS-plus scoring system
[10]. DIPSS has largely replaced the Lille score for assessing
the risk of mortality in primary MF.
The utility of new scoring systems in predicting the out-
comes of patients undergoing RIC HCT is not well under-
stood. Two recent studies have reported that post-HCT
success was dependent on pre-HCT DIPSS scores [6,11].
A large proportion of patients received FIC in those studies.
Another study from the European Group for Blood and
Marrow Transplantation reported that DIPSS, although
predictive, did not sufﬁciently differentiate betweenintermediate-1 and intermediate-2 risk populations in
patients undergoing RIC HCT for MF [2].
In addition, various RIC regimens of varying intensities
have been used in patients withMF [4,12-16]. The superiority
of one regimen over other has not been established. The
impact of other transplant-related factors such as condi-
tioning regimen, donor type, and graft-versus-host disease
(GVHD) prophylaxis has not been well studied in the RIC
setting. Thus, the Chronic Leukemia Working Committee of
the CIBMTR sought to determine the outcomes of patients
with primary MF undergoing HCT using RIC, and analyzed
the impact of patient-, disease-, and transplantation-related
factors on outcomes.
METHODS
Data Source
The CIBMTR is a combined research program of the Medical College of
Wisconsin and the National Marrow Donor Program. CIBMTR comprises a
voluntary network ofmore than 450 transplantation centers worldwide that
contribute detailed data on consecutive allogeneic and autologous HCTs to a
centralized statistical center. Observational studies conducted by the
CIBMTR are performed in compliance with all applicable federal regulations
pertaining to the protection of human research participants. Protected
health information used in the performance of such research is collected and
maintained in CIBMTR’s capacity as a public health authority under the
HIPAA privacy rule. Additional details on the data source are described
elsewhere [17].
Patient Populations
We identiﬁed adult patients age >18 yr undergoing a ﬁrst allogeneic
HCT for primary MF from a related or unrelated donor between 1997 and
2010 using an RIC regimen. The intensity of the conditioning regimen was
deﬁned according to CIBMTR consensus criteria [16]. Patients whose disease
had progressed to acute myelogenous leukemia before HCT were excluded.
Additional exclusion criteria included syngeneic transplants, cord blood
transplants, haploidentical transplants, and in vitro T celledepleted grafts.
Unrelated donor (URD) transplant recipients were classiﬁed based on
available HLA typing as described previously [18].
Prognostic Scoring Systems
Risk stratiﬁcation according to DIPSS score was calculated at the time of
HCT [9]. DIPSS risk categorization could not be determined in 3 patients
(<1%) because of missing data. Because of missing cytogenetics in 36% of the
patients, we were not able to evaluate DIPSS-plus in this study.
Cytogenetics
Results of cytogenetics testing provided by the transplantation center
were reviewed and classiﬁed as normal karyotype or abnormal karyotype.
Abnormal karyotype was further subdivided into unfavorable and other
abnormalities. Unfavorable cytogenetics was deﬁned as described previ-
ously and included complex abnormalities (3) or 1 or 2 abnormalities,
including þ8, -7/7q-, i(17q), -5/5q-, 12p-, inv(3), and 11q23 rearrangements
[10].
Endpoints
The primary endpoint of the study was overall survival (OS). Other
endpoints of interest were hematopoietic recovery, acute GVHD (aGVHD),
chronic GVHD (cGVHD), relapse/progression, nonrelapse mortality (NRM),
and progression-free survival (PFS). OS was deﬁned as time from HCT to
death from any cause, and patients were censored at the last follow-up.
Relapse/progression was reported by the transplantation centers, with
NRM considered a competing event. NRM was deﬁned as death within the
ﬁrst 28 days of transplantation from any cause or death without evidence of
disease progression/recurrence; relapse/progression was considered a
competing event. PFS was deﬁned as time to treatment failure (death or
relapse/progression). For relapse/progression, NRM, and PFS, patients alive
in continuous complete remission were censored at last follow-up. He-
matopoietic recovery was deﬁned as time to an absolute neutrophil count
Table 1
Patient-, Disease-, and Transplantation-Related Characteristics
Characteristic Value
Number of patients 233
Number of centers 83
Age, yr, median (range) 55 (19-79)
Age 18-40 yr, n (%) 12 (5)
Age 41-60 yr, n (%) 157 (67)
Age >60 yr, n (%) 64 (27)
Sex, n (%)
Male 151 (65)
Female 82 (35)
Karnofsky score, n (%)
<90% 84 (36)
90%-100% 135 (58)
Missing 14 (6)
Time from diagnosis to HCT, mo, median (range) 15 (2-305)
Constitutional symptoms at HCT, n (%)
No 182 (78)
Yes 42 (18)
Missing 9 (4)
Circulating blasts in blood at HCT, n (%)
Absent 132 (57)
1% 101 (43)
Spleen status at HCT, n (%)
Spleen not palpable 52 (22)
Splenomegaly 113 (48)
Splenectomy 59 (25)
Missing 9 (4)
Cytogenetics at HCT, n (%)
Not evaluable/missing 84 (36)
Normal karyotype 89 (38)
Abnormal karyotype 66 (28)
Unfavorable 30 (13)
Other abnormalities 30 (13)
Hemoglobin at HCT, g/L, n (%)
<100 148 (64)
100 85 (36)
Platelet count at HCT,  109/L, median (range) 121 (5-1835)
Platelet count at HCT, n (%)
<100 x 109/L 94 (40)
100 x 109/L 116 (50)
Missing 23 (10)
WBC at HCT, x 109/L, median (range) 6 (<1-431)
DIPSS at HCT, n (%)
Low risk 27 (12)
Intermediate-1 114 (49)
Intermediate-2 86 (37)
High-risk 3 (1)
Missing 3 (1)
Graft source, n (%)
Bone marrow 28 (12)
Peripheral blood 205 (88)
Donor type, n (%)
MSD 79 (34)
Well-matched URD 104 (45)
Partially matched URD 40 (17)
Mismatched URD 10 (4)
Donor/recipient CMV serostatus, n (%)
þ/þ 72 (31)
þ/ 26 (11)
/þ 55 (24)
/ 60 (26)
Missing 20 (9)
Conditioning regimen, n (%)
FluTBI-based 51 (22)
FluMel-based 65 (28)
FluBu-based 89 (38)
Other 28 (12)
ATG or alemtuzumab use, n (%)
ATG 110 (47)
Alemtuzumab 13 (6)
GVHD prophylaxis, n (%)
Tacrolimus-based 105 (45)
Cyclosporine-based 124 (53)
Other 4 (2)
(Continued)
Table 1
(continued)
Characteristic Value
Year of HCT, n (%)
1997-2001 26 (11)
2002-2006 116 (50)
2007-2010 91 (39)
Follow-up of survivors, mo, median (range) 50 (3-134)
V. Gupta et al. / Biol Blood Marrow Transplant 20 (2014) 89e97 91(ANC) >0.5  109/L sustained for 3 consecutive days and time to achieve a
platelet count of >20  109/L independent of platelet transfusions for
3 consecutive days. aGVHD and cGVHD were diagnosed and graded ac-
cording to consensus criteria [19,20].Statistical Methods
Univariate probabilities of OS and PFS were calculated using the Kaplan-
Meier estimator. The log-rank test was used for univariate comparisons.
Probabilities of hematopoietic recovery, aGVHD, cGVHD, NRM, and relapse/
progression were calculated using cumulative incidence curves to accom-
modate competing risks. Potential risk factors for OS, NRM, relapse and
PFS were evaluated in multivariate analyses using Cox proportional hazards
regression. The proportional hazards assumption was tested. A stepwise
selection procedure was used to select signiﬁcant covariates. Factors signif-
icantly associated with the outcome variable at a 5% level were retained in
the ﬁnal model. All P values are 2-sided.
First-order interactions between the main effect and signiﬁcant cova-
riates were tested. An analysis evaluating the impact of aGVHD/cGVHD as
time-dependent covariates on survival, NRM, relapse/progression, and PFS
was conducted. Adjusted 5-year survival probabilities were estimated using
the direct adjusted survival curves estimation method [21]. SAS version 9.3
(SAS Institute, Cary, NC) was used for all analyses.
The following patient-, disease-, and transplantation-related factors
were included in the multivariate model: patient age (40 yr versus 41 to
60 yr versus >60 yr), sex, Karnofsky performance score (<90 versus 90),
DIPSS (low/intermediate-1 versus intermediate-2/high), platelet count
(<100  109/L versus 100  109/L), spleen status (normal spleen versus
splenomegaly versus splenectomy versus missing), time from diagnosis to
HCT, conditioning regimen (ﬂudarabine and total body irradiation [FluTBI]-
based versus ﬂudarabine and melphalan [FluMel]-based versus ﬂudarabine
and busulfan [FluBu]-based versus other), donor type (matched sibling
donor [MSD] versus well-matched URD versus partially matched/mis-
matched URD), GVHD prophylaxis (tacrolimus-based versus cyclosporine-
based versus all others), and year of HCT (2003 versus 2003).RESULTS
Patient-, Disease-, and Transplantation-Related
Characteristics
A total of 233 patients from 83 transplantation centers
met the study eligibility criteria, including 79 with an MSD
and 154 with a URD. Among the URD transplant recipients,
104 (67%) were well HLA-matched with their donors, and 50
(33%) were partially matched or mismatched. The median
age at HCT was 55 yr (range, 19 to 79 yr), and 64 patients
(27%) were age >60 yr. The median follow-up of survivors
was 50 mo (range, 3 to 134 mo). The completeness index of
follow-up for the study population at was 94% at 3 yr and 90%
at 5 yr [22].
Baseline patient, disease, and transplantation character-
istics are presented in Table 1. Conditioning regimens were
FluTBI-based (n ¼ 51; 22%), FluMel-based (n ¼ 65; 28%),
FluBu-based (n ¼ 89; 38%), and other (n ¼ 28; 12%). The
median (interquartile range [IQR]) doses of various cytotoxic
agents used in these regimen were as follows: for FluTBI,
ﬂudarabine 90 mg/m2 (IQR, 88 to 118 mg/m2) and single-
fraction TBI 200 cGY (IQR, 200 to 200 cGy) or fractionated
TBI 800 cGy (IQR, 800 to 800 cGy); for FluMel, ﬂudarabine 129
mg/m2 (IQR 122 to 147 mg/m2) and melphalan 139 mg/m2
(IQR, 132 to 140 mg/m2); for FluBu, ﬂudarabine 157 mg/m2
(IQR, 124 to 178 mg/m2) and oral busulfan 8 mg/kg (IQR, 7 to
8 mg/kg) or i.v. busulfan 6 mg/kg (IQR, 5 to 6 mg/kg).
Table 2
Post-HCT Outcomes: Univariate Analysis (Study Population, n ¼ 233)
Outcome Number Evaluated Probability (95% CI), %
Neutrophil engraftment 232
28-d 84 (78-88)
100-d 97 (92-99)
Platelet recovery 215
28-d 47 (40-53)
100-d 77 (70-82)
Grade II-IV aGVHD 232
100-d 37 (30-43)
Grade III-IV aGVHD 232
100-d 19 (15-25)
cGVHD 224
1-yr 42 (35-48)
3-yr 50 (43-57)
5-yr 51 (44-58)
Relapse/progression 218
1-yr 43 (36-49)
3-yr 47 (40-53)
5-yr 48 (42-55)
NRM 218
1-yr 18 (13-23)
3-yr 22 (16-27)
5-yr 24 (18-31)
PFS 218
1-yr 39 (33-46)
3-yr 32 (26-38)
5-yr 27 (21-34)
OS 233
1-yr 62 (55-68)
3-yr 52 (45-58)
5-yr 47 (40-53)
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(n ¼ 27), 49% intermediate-1 (n ¼ 114), 37% intermediate-2
(n ¼ 86), and 1% high (n ¼ 3). DIPSS was missing in 3
patients (1%). Owing to the small numbers of DIPSS low-risk
and high-risk patients, the DIPSS groups were collapsed into
low/intermediate-1 (n ¼ 141; 61%) and intermediate-2/high
(n ¼ 89; 38%) groups.Figure 1. OS, PFS, relapse and NRMTransplantation Outcomes
Primary endpoint: OS
The probability of OS at 5 yr was 47% (95% CI, 40% to 53%)
(Table 2 and Figure 1). In a multivariate analysis, donor type
was independently associated with higher NRM (p<.0001),
and the RRs of NRMwere 3.92 (95% CI, 1.48 to 10.32; p%.006)
and 9.37 (95% CI , 3.4 to 25.16; p<.0001) for well-matched
URD and partially matched/mismatched URD, respectively
(Table 3). Adjusted probabilities of survival at 5 yr were 56%
(95% CI, 44% to 67%) for MSD HCT, 48% (95% CI, 37% to 58%)
for well-matched URD HCT, and 34% (95% CI, 21% to 47%) for
partially matched/mismatched URD HCT (P ¼ .002)
(Figure 2).
Although not statistically signiﬁcant, there was a trend in
lower overall mortality between DIPSS low/intermediate-1
risk versus DIPSS intermediate-2/high-risk disease (RR,
1.37; 95% CI, 0.95 to 1.98; P ¼ .10) (Table 3). The adjusted
probability of survival at 5 yr was 51% (95% CI, 42% to 59%) for
low/intermediate-1 and 41% (95% CI, 30% to 52%) for
intermediate-2/high risk (Figure 3). The conditioning
regimen was not signiﬁcantly associated with OS (Table 3);
however, when individual conditioning regimens were
compared, the FluMel-based regimen showed a trend toward
lower mortality compared with the FluBu-based regimen
(RR, 0.63; P ¼ .06). Adjusted probabilities of survival at 5 yr
according to conditioning regimen were as follows: FluMel-
based, 59% (95% CI, 32% to 59%); FluTBI-based, 46% (95% CI,
32% to 59%); FluBu-based, 41% (95% CI, 28% to 53%); others,
28% (95% CI, 8% to 47%) (Figure 4).
Secondary endpoints
Hematopoietic recovery. The cumulative incidence of
neutrophil recovery was 84% (95% CI, 78% to 88%) at 28 days
and 97% (95% CI, 92% to 99%) at 100 days (Table 2), and that
of platelet recovery was 47% (95% CI, 40% to 53%) at 28 days
and 77% (95% CI, 70% to 82%) at 100 days. There was no
signiﬁcant difference in neutrophil (P¼ .52, log-rank test) orafter RIC HCT for primary MF.
Table 3
Multivariate Analysis for aGVHD, cGVHD, Relapse/Progression, NRM, PFS, and OS
n RR P Value 95% CI Overall P Value
Grade II-IV aGVHD
Donor type .02
MSD 79 1
Well-matched URD 104 1.98 .006 1.22-3.22
Partially matched/mismatched URD 50 1.52 .18 0.83-2.80
Contrast
Well-matched URD versus partially matched/mismatched URD 1.30 .33 0.76-2.23
cGVHD
Donor type .33
MSD 79 1
Well-matched URD 104 0.81 .35 0.51-1.26
Partially matched/mismatched URD 50 1.21 .49 0.67-2.10
Relapse/progression
DIPSS
Low/intermediate-1 141 1 .04
Intermediate-2/high 89 0.65 .04 0.42-0.99
NRM
DIPSS
Low/intermediate-1 141 1 .07
Intermediate-2/high 89 1.70 .07 0.96-3.01
Donor type
MSD 79 1 <.001
Well-matched URD 104 3.92 .006 1.50-10.33
Partially matched/mismatched URD 50 9.37 <.001 3.49-25.17
Contrast
Well-matched URD versus partially matched/mismatched URD 0.42 .005 0.23-0.77
PFS
DIPSS
Low/intermediate-1 141 1 .55
Intermediate-2/high 89 0.90 .55 0.65-1.26
Donor type .03
MSD 79 1
Well-matched URD 104 1.17 .42 0.80-1.69
Partially matched/mismatched URD 50 1.75 .01 1.14-2.68
Contrast
Well-matched URD versus partially matched/mismatched URD 0.67 .05 0.45-0.99
OS
DIPSS
Low/intermediate-1 141 1 .10
Intermediate-2/high 89 1.37 .10 0.95-1.98
Donor type
MSD 79 1 .002
Well-matched URD 104 1.57 .05 1.01-2.46
Partially matched/mismatched URD 50 2.48 .0003 1.51-4.04
Conditioning regimen
FluTBI-based 51 1 .14
FluMel-based 65 0.71 .23 0.41-1.23
FluBu-based 89 1.13 .63 0.70-1.82
Other 28 1.41 .28 0.76-2.62
Contrast
FluMel-based versus FluBu-based 0.63 .06 0.39-1.02
FluMel-based versus others 0.55 .03 0.27-0.95
FluBu-based versus others 0.80 .44 0.46-1.41
Well-matched URD versus partially matched/mismatched URD 0.64 .04 0.41-0.98
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type.
aGVHD and cGVHD. The cumulative incidences of grade II-IV
and grade III-IV aGVHD at 100 days were 37% (95% CI, 30% to
43%) and 19% (95% CI, 15% to 25%), respectively (Table 2). The
cumulative incidence of cGVHD at 5 yr was 51% (95% CI, 44%
to 58%) (Table 2). In a multivariate analysis, URD HCT was
associatedwith a signiﬁcantly higher (P¼ .02) risk of aGVHD;
compared with MSD HCT, the RR for well-matched URD HCT
was 1.98 (95% CI, 1.21 to 3.22; P ¼ .006), and that for partially
matched/mismatched URD HCT was 1.52 (95% CI, 0.82 to
2.80; P¼ .18) (Table 3). No signiﬁcant differences in the risk of
cGVHD related to donor type were observed (P ¼ .33)
(Table 3).The impact of aGVHD/cGVHD on transplantation out-
comes was evaluated (Supplemental Table 1). Patients who
developed aGVHD but not cGVHD had signiﬁcantly higher
NRM and lower relapse/progression compared with those in
the no aGVHD or cGVHD group. No differences in PFS or
survival were observed.
NRM, relapse/progression, and PFS. At 5 yr, the cumulative
incidence of NRM was 24% (95% CI, 18% to 31%) and that of
relapse/progression was 48% (95% CI, 42% to 55%), and the
probability of PFS was 27% (95% CI, 21% to 34%) (Table 2 and
Figure 1). In a multivariate analysis, donor type was inde-
pendently associated with higher NRM (P < .0001), and the
RRs of NRM were 3.92 (95% CI, 1.48 to 10.32; P ¼ .006) and
9.37 (95% CI, 3.4 to 25.16; P < .0001) (Table 3). The causes of
Figure 2. Adjusted survival according to donor type (MSD versus well-matched URD versus partially matched/mismatched URD.
V. Gupta et al. / Biol Blood Marrow Transplant 20 (2014) 89e9794death according to donor type are shown in Figure 5. The
main causes of NRM were GVHD, infections, and organ fail-
ure, and the rates of all these complications were higher in
partially matched/mismatched URD HCT (Figure 5). There
was a trend toward higher NRM in patients in the DIPSS
intermediate-2/high risk category (RR, 1.70; 95% CI, 0.96 to
3.01; P ¼ .07) (Table 3). No affect of donor type on relapse/
progressionwas seen; however, unexpectedly, we found that
patients with DIPSS intermediate-2/high risk had lower risk
of relapse compared with those with DIPSS low/
intermediate-1 risk (RR, 0.65; 95% CI, 0.42 to 0.98; P ¼ .04)
(Table 3).Figure 3. Adjusted survival according to DIPSS risk stratiﬁcaDonor type had a signiﬁcant impact on PFS (P ¼ .03), and
PFS was signiﬁcantly inferior for partially matched/mis-
matched URD HCT. The RR for PFS was 1.17 (95% CI, 0.80 to
1.69; P¼ .42) forwell-matchedURDHCTand 1.75 (1.14 to 2.68;
P ¼ .01) for partially matched URD/mismatched URD HCT
(Table 3). DIPSS risk category had no impact on PFS (P ¼ .55).
Impact of cytogenetics. In an exploratory analysis, we evalu-
ated the impact of cytogenetics on survival after adjusting for
donor type. Patients with unfavorable cytogenetics had
nearly 2-fold higher mortality compared with those with a
normal karyotype (RR, 1.98; 95% CI, 1.16 to 3.38). There wastion (low/intermediate-1 versus intermediate-2/high).
Figure 4. Adjusted survival according to type of RIC regimen.
V. Gupta et al. / Biol Blood Marrow Transplant 20 (2014) 89e97 95no signiﬁcant difference between patients with a normal
karyotype and those with abnormalities other than unfa-
vorable (RR, 1.4; 95% CI, 0.78 to 2.5).
DISCUSSION
This report represents the largest international multi-
center experience of RIC HCT in patients with primary MF,
and reinforces the curative potential of RIC HCT in patients
with MF. Recently published studies in which patients pri-
marily received FIC regimens have demonstrated the impact
of higher DIPSS scores on survival in patients with MF [6,11].
In the present study, trends toward increased NRM (P ¼ .07)
and inferior survival (P ¼ .10) were observed in DIPSS
intermediate-2/high-risk patients comparedwith DIPSS-low/
intermediate-1 risk patients. Of note, there were very few
patients with DIPSS-low risk and DIPSS-high risk category in
this study, and so the main measured effect in our study is
between DIPSS-intermediate 1 and DIPSS-intermediate 2.
Another multicenter study from Germany evaluated prog-
nostic factors in 150 patients undergoing RIC HCT for MF
and reported that DIPSS discriminated poorly between
intermediate-1 and intermediate-2 risk patients. The dis-
crepancy between previous reports and the present study is
related to a number of factors, including dissimilar study
populations [2,6,11]. The present study was restricted to pa-
tients with primary MF, whereas approximately 40% of the
populations reported in previous studies included patients
with post-Essential Thrombocythemia/post-polycythemic
MF. It is noteworthy that various risk stratiﬁcation systems
are derived from patients with primary MF [7-10], and have
not been validated for secondaryMF. Approximately 70%-85%
of patients in previously reported studies were treated with
FIC [6,11]. Our sample size is signiﬁcantly larger than that of
contemporary studies, although we had very few patients
with DIPSS high-risk disease. A study fromGermany reported
that wild-type JAK2, age57 yr, and constitutional symptoms
were all associated with inferior survival [2]. In the present
study, age did not have an independent prognostic impact in
our patient population undergoing RIC HCT. We could notevaluate the prognostic signiﬁcance of JAK2 mutation
because of missing data on JAK2 mutation status in a large
proportion of patients.
Perhaps one of the most important ﬁndings of this study
is the independent adverse impact of donor type on NRM
and survival. The mortality risk associated with well-
matched URD and partially matched/mismatched URD
transplants was signiﬁcantly higher compared with MSD
transplants. A prospective study of RIC using FluBu-based
conditioning reported similar outcomes with MSD and
well-matched URD transplants, whereas results were infe-
rior for a small number of patients with mismatched URD
transplants [12]. Preliminary results of another prospective
study from the Myeloproliferative Diseases Research Con-
sortium using FluMel-based conditioning indicated signiﬁ-
cantly inferior outcomes of URD transplants [15]. This ﬁnding
is of important clinical value, given that the optimal timing of
HCT has been a matter of debate with the wider availability
of JAK1/2 inhibitor therapy [1]. One may consider reserving
the option of partially matched/mismatched URD HCT after
the failure of JAK inhibitor therapy, whereas HCT may be
considered earlier in the disease course in patients with a
suitable MSD regardless of the response to JAK1/2 inhibitor
therapy.
The optimal RIC regimen in patients with MF remains
unknown. In the present study, patients receiving a FluMel-
based regimen showed a trend toward better outcomes
compared with patients receiving a FluBu-based regimen or
another regimen. Caution is needed when interpreting these
results, considering the heterogeneity of the doses of cyto-
toxic agents in these regimens. These ﬁndings await further
conﬁrmation in well-designed prospective studies. We did
not ﬁnd an independent adverse impact of either thrombo-
cytopenia [23] or splenomegaly [24] and no beneﬁcial
impact of pretransplantation splenectomy [6] as has been
reported in previous studies.
Our study also highlights the high rate of relapse/pro-
gression seen after RIC HCT. Unexpectedly, we found a lower
risk of relapse in the DIPSS intermediate-2/high risk
Figure 5. Cause of death in patients with MF undergoing RIC HCT using
an MSD (A), a well-matched URD (B), and a partially matched/mismatched
URD (C).
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however. As described in Methods, relapse/progression was
analyzed as reported on the CIBMTR forms by the trans-
plantation centers. The CIBMTR forms do not collect detailed
information on the basis of relapse/progression, however.
There is no consistent deﬁnition of relapse/progression for
patients with MF. The International Working Group for MPN
Research and Treatment has attempted to deﬁne response
criteria for use in clinical trials. There are no publishedreports on the application of these criteria in patients un-
dergoing bone marrow transplantation, and the criteria are
difﬁcult to apply in retrospective registry studies.
This study has some inherent limitations that could in-
ﬂuence the interpretation of data. Although our sample size
is signiﬁcantly larger compared with previous reports, it is
still relatively small. The HCTs were performed before JAK1/2
inhibitor therapy became widely available. How the wider
availability of JAK1/2 inhibitor therapy will inﬂuence the ﬁeld
of transplantation for MF, especially the optimal timing, is
uncertain. Given that JAK1/2 inhibitor therapy is neither
curative nor decreases the risk of leukemic transformation,
HCT will continue to remain an important treatment option
for suitable patients. Nevertheless, our ﬁndings are relevant
to modern clinical practice, and demonstrate the curative
potential of RIC HCT in a multicenter setting. The ﬁndings of
increased mortality associated with partially/matched or
mismatched URDs help further deﬁne the positioning of HCT
in the emerging therapeutic options for MF.
In conclusion, RIC HCT is a potentially curative option for
some patients with MF. Donor type is the most important
factor predicting survival after RIC HCT for MF. Future pro-
spective trials are needed to determine the preferred RIC
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